Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
420.07
Oct 30 • 3:59 PM ET Dollar change-1.95 Percentage change(-0.46%)
Aftermarket Close
423.80
Aftermarket • 7:32 PM ET Dollar change+3.73 Percentage change(0.89%)
Index
S&P 500
Market Cap
90.76B
Enterprise Value
-
Income
5.14B
Sales
201.83B
Book/sh
206.75
Cash/sh
-
Employees
97100
IPO
Oct 30, 2001
P/E
17.91
Forward P/E
13.89
PEG
3.05
P/S
0.45
P/B
2.03
P/C
-
P/FCF
13.93
EV/EBITDA
-
EV/Sales
-
Quick Ratio
-
Current Ratio
1.47
Debt/Eq
0.69
LT Debt/Eq
0.68
Option/Short
Yes / Yes
EPS (ttm)
23.46
EPS next Y
30.25
EPS next Q
2.08
EPS this Y
-4.09%
EPS next Y
4.12%
EPS next 5Y
4.55%
EPS past 3/5Y
1.27% 6.99%
Sales past 3/5Y
8.34% 10.32%
EPS Y/Y TTM
-4.06%
Sales Y/Y TTM
3.60%
EPS Q/Q
18.02%
Sales Q/Q
1.42%
Insider Own
0.23%
Insider Trans
-1.76%
Inst Own
95.01%
Inst Trans
0.47%
ROA
4.10%
ROE
11.60%
ROIC
6.85%
Gross Margin
-
Oper. Margin
3.81%
Profit Margin
2.55%
SMA20
-0.50%
SMA50
2.32%
SMA200
12.82%
Trades
Shs Outstand
216.11M
Shs Float
215.55M
52W High
450.69 -6.79%
52W Low
274.84 52.84%
Volatility
2.71% 2.75%
ATR (14)
11.55
RSI (14)
50.77
Beta
0.65
Rel Volume
1.12
Avg Volume
1.15M
Volume
1,286,917
Perf Week
-4.52%
Perf Month
10.06%
Perf Quarter
9.74%
Perf Half Y
12.72%
Perf YTD
19.83%
Perf Year
30.48%
Perf 3Y
-6.24%
Perf 5Y
-3.46%
Perf 10Y
245.40%
Prev Close
422.02
Price
420.07
Change %
-0.46%
Consensus
Buy
Avg. Price Target
$479.62
Implied Upside
+14.2%
Analysts13incl. previous ratings
Rating Distribution6 Buy · 7 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 20, 2026Upgrade
DB logoDDeutsche Bank
Hold → Buy$498+18.6%
Apr 29, 2026Upgrade
BAC logoBBofA Securities
Neutral → Buy$435+3.6%
Apr 08, 2026Initiated
EVR logoEEvercore ISI
In-line$345-17.9%
Feb 03, 2026Downgrade
RY logoRRBC Capital Mkts
Outperform → Sector Perform$358-14.8%
Jan 08, 2026Upgrade
WWolfe Research
Peer Perform → Outperform$425+1.2%
Dec 19, 2025Downgrade
DB logoDDeutsche Bank
Buy → Hold$320-23.8%
Oct 14, 2025Initiated
GS logoGGoldman
Neutral
Jul 21, 2025Downgrade
AArgus
Buy → Hold
Jul 18, 2025Downgrade
LLeerink Partners
Outperform → Market Perform$310-26.2%
Apr 15, 2025Downgrade
RRobert W. Baird
Outperform → Neutral$529+25.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye MarkEVP & CFOOct 22 '26Sale440.1310,5844,658,35719,919Oct 23 04:30 PM
MARK B KAYEOfficerOct 22 '26Proposed Sale440.1310,5844,658,378Oct 22 04:03 PM
PERU RAMIRO GDirectorJul 17 '26Buy366.051,000366,05010,908Jul 17 03:04 PM
BOUDREAUX GAILPresident and CEOJul 17 '26Buy367.792,7251,002,230171,976Jul 17 01:50 PM
CLARK R KERRYDirectorJul 07 '26Proposed Sale419.911,500629,865Jul 07 04:58 PM
Penczek Ronald WCAO & ControllerJun 12 '26Sale403.16369148,7663,740Jun 15 04:10 PM
RONALD WILLIAM PENCZEKOfficerJun 12 '26Proposed Sale403.16369148,767Jun 12 05:27 PM
Dixon Robert L JRDirectorJun 11 '26Sale401.7715160,66710,734Jun 12 04:12 PM
Dixon Robert L JRDirectorJun 11 '26Proposed Sale401.7615160,666Jun 11 05:10 PM
Penczek Ronald WCAO & ControllerMay 19 '26Option Exercise294.301,531450,5795,640May 20 04:11 PM
Penczek Ronald WCAO & ControllerMay 19 '26Sale403.131,531617,1924,109May 20 04:11 PM
RONALD WILLIAM PENCZEKOfficerMay 19 '26Proposed Sale403.131,531617,192May 19 04:25 PM
SCHULMAN AMY WDirectorMar 12 '26Sale287.50267,475218Mar 23 04:10 PM
Kendrick Charles Morgan JREVP & President, CommercialMar 06 '26Sale284.923,196910,60411,791Mar 09 04:45 PM
CHARLES MORGAN KENDRICKOfficerMar 06 '26Proposed Sale284.923,196910,593Mar 06 04:17 PM
COLLIS STEVEN HDirectorMar 05 '26Buy289.843,000869,5203,639Mar 06 08:03 AM
Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.
PresidentMs. Gail Koziara Boudreaux
Executive VP & CFOMr. Mark Bradley Kaye
Special AdvisorMr. Peter David Haytaian Esq.
EVP and President of Commercial & Specialty Health BenefitsMr. Charles Morgan Kendrick Jr.
Executive VP & Chief Health Benefits OfficerMs. Felicia Farr Norwood